Howard Monique L, Hill John J, Galluppi Gerald R, McLean Matthew A
Amgen Inc., 1201 Amgen Court West, Seattle, WA 98119, USA.
Comb Chem High Throughput Screen. 2010 Feb;13(2):170-87. doi: 10.2174/138620710790596745.
This review describes methods for quantifying the binding of small molecule drug candidates to plasma proteins and the application of these methods in drug discovery and development. Particular attention is devoted to methods amenable to medium-to-high throughput analysis and those well suited for measurement of compounds that are highly protein bound. The methods reviewed herein include the conventional techniques of equilibrium dialysis, ultrafiltration and ultracentrifugation, as well as some more novel approaches utilizing micropartitioning and biosensor-based analysis. Additional concepts that are discussed include plasma protein structure, enantioselective protein binding, drug displacement, the effect of patient demographics and disease states on free (unbound) drug levels, and the influence of protein binding on drug candidate pharmacokinetics and pharmacodynamics. Practical considerations pertaining to the evaluation of highly protein bound drug candidates are also highlighted.
本综述描述了量化小分子候选药物与血浆蛋白结合的方法,以及这些方法在药物发现和开发中的应用。特别关注适用于中高通量分析的方法,以及那些非常适合测量与蛋白质高度结合的化合物的方法。本文综述的方法包括平衡透析、超滤和超速离心等传统技术,以及一些利用微分配和基于生物传感器分析的更新颖方法。讨论的其他概念包括血浆蛋白结构、对映体选择性蛋白结合、药物置换、患者人口统计学和疾病状态对游离(未结合)药物水平的影响,以及蛋白结合对候选药物药代动力学和药效学的影响。还强调了与评估与蛋白质高度结合的候选药物相关的实际考虑因素。